Landos Biopharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Landos Biopharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2021 to Q1 2024.
  • Landos Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $260K, a 16.1% increase year-over-year.
  • Landos Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $1.01M, a 19.7% decline year-over-year.
  • Landos Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $971K, a 50.7% decline from 2022.
  • Landos Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.97M, a 52.1% decline from 2021.
  • Landos Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4.12M, a 394% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $1.01M $260K +$36K +16.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $971K $245K +$49K +25% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 $922K $248K +$48K +24% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $874K $254K -$380K -59.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $1.25M $224K -$717K -76.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $1.97M $196K -$2.23M -91.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $4.2M $200K -$155K -43.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $4.36M $634K +$322K +103% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $4.04M $941K -$82K -8.02% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $4.12M $2.43M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $355K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $312K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $1.02M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.